BTIG Maintains Buy on Boston Scientific, Lowers Price Target to $60

Benzinga Newsdesk www.benzinga.com Negative 70.6%

Neg 70.6% Neu 0% Pos 0%

BTIG analyst Marie Thibault maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $65 to $60.